The TruDelivery® RTU portfolio helps meet the real-world challenges of hospital pharmacies — and is ready when you are. It’s about time.
Company Background
Par Health was born from the merger of Mallinckrodt and Endo — two legacy companies with over a century of experience in essential medicines. Both began as family-run businesses, united by a commitment to integrity and innovation. Our manufacturing footprint includes the historic API site in St. Louis, Missouri — founded over 150 years ago by three brothers with a bold vision. It remains central to our operations today. We also carry forward the legacy of our Rochester, Michigan facility, which earned the first FDA Biologics license for polio vaccine
manufacturing. These sites are joined by eight additional facilities across the United States and India, forming a global manufacturing and supply network that delivers high-quality medicines with consistency and scale.
Product Overview
Our RTU products, available through our TruDelivery platform (TruDelivery.com), streamline hospital operations by eliminating the need for preparation time or transfer before patient administration. This can reduce preparation time, enhance convenience and workflow, and minimize potential preparation errors. All these advantages support quality care for patients in hospitals, clinics, and home health and long-term care systems.
TruDelivery® RTU products require no compounding, diluting, or mixing1-7 and provide extended dating compared with compounded products.8-15* Most hospital pharmacy buyers can purchase TruDelivery RTU products with their routine daily wholesale orders. These TruDelivery RTU products are already available through your health system’s full-line wholesaler and on your group purchasing organization (GPO) contract.
It’s About Time for Simplicity and Efficiency
TruDelivery RTU products are designed to help address some of the challenges facing hospital pharmacies. Products that require the use of a separately packaged diluent, or that require mixing, compounding, or transferring to another container for administration, all require multiple steps before the medication can be administered to a waiting patient. Even under the best circumstances, extra steps may introduce risk of error.16-20 In the Food and Drug Administration’s (FDA) guidance to medication manufacturers, the agency encourages the manufacture of products specifically designed to minimize medication errors. Reducing the steps required for preparation and administration may help reduce risk of medication errors.19
Explore the Growing Portfolio of TruDelivery RTU Products
Contact your Par Health key account manager for more information on the below TruDelivery products:
- Adrenalin® (epinephrine in 0.9% sodium chloride injection) RTU Premixed Bags
- Bivalirudin Injection RTU Bottles
- Dexmedetomidine Hydrochloride Injection RTU Bottles
- Ephedrine Sulfate Injection RTU Vials
- Naloxone Hydrochloride Injection, USP RTU Prefilled Syringes
- PREVDUO® (neostigmine methylsulfate and glycopyrrolate) Injection RTU Prefilled Syringes
- Vasostrict® (vasopressin injection, USP) RTU Bottles
*For Category 3 compounded sterile preparations (CSP), the maximum beyond-use date (BUD) is 90 days at controlled room temperature (CRT), 120 days in refrigerator, and 180 days in freezer15 versus shelf life of 2 years at CRT for Adrenalin®, Dexmedetomidine, Ephedrine, Naloxone, and PREVDUO®8-12; 12 months at CRT and 2 years in refrigerator for Vasostrict®14; 72 hours at CRT and 18 months in refrigerator for Bivalirudin.2,13
References:
1) Adrenalin® (epinephrine in sodium chloride injection). Prescribing Information. Endo USA, Inc. 2) Bivalirudin Injection. Prescribing Information. Endo USA, Inc. 3) Dexmedetomidine Hydrochloride Injection. Prescribing Information. Endo USA, Inc. 4) Ephedrine Sulfate Injection. Prescribing Information. Endo USA, Inc. 5) Naloxone Hydrochloride Injection. Prescribing Information. Endo USA, Inc. 6) PREVDUO®. Prescribing Information. Endo USA, Inc. 7) Vasostrict®. Prescribing Information. Endo USA, Inc. 8) U.S. Food & Drug Administration. New Drug Approval for Epinephrine: NDA 215875. April 21, 2023. 9) Data on file. DOF-DX-01. Endo USA, Inc.; July 26, 2023. 10) Data on file. DOF-EH-01. Endo USA, Inc.; July 31, 2023. 11) Data on file. DOFNHC-01. Endo USA, Inc.; November 13, 2024. 12) Data on file. DOF-PRVD-01. Endo USA, Inc.; July 20, 2023. 13) Healthcare Distribution Alliance. Standard pharmaceutical product and medical device information: Bivalirudin Injection. July 10, 2023. 14) Data on file. DOF-VS-02. Endo USA, Inc.; September 20, 2023. 15) The United States Pharmacopeial Convention. USP compounding standards and beyond-use dates. https://go.usp.org/2022_ Revisions_795_797. Accessed April 29, 2024. 16) Fanikos J, Burger M, Canada T, et al. An assessment of currently available i.v. push medication delivery systems. Am J HealthSyst Pharm. 2017;74(9):e230-235. 17) Institute for Safe Medication Practices. ISMP safe practice guidelines for adult IV push medications. https://www.ismp.org/sites/default/files/ attachments/2017-11/ISMP97-Guidelines-071415-3.%20FINAL.pdf. Accessed April 29, 18) Hertig JB, Degnan DD, Scott CR, Lenz JR, Li X, Anderson CM. A comparison of error rates between intravenous push methods: a prospective, multisite, observational study. J Patient Saf. 2018;14(1):60-65. 19) U.S. Food & Drug Administration, Department of Health and Human Services, Center for Drug Evaluation and Research. Safety considerations for product design to minimize medication errors: guidance for industry. https://www.fda.gov/ media/84903/ download. Published April 2016. Accessed April 29, 2024. 20) American Society of Health-System Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Health-Syst Pharm. 2018;75(19):1493-1517.
